Figure 5
From: The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients
PAH medication group and PAH diagnosis group average annual health care costs (exploratory analysis). For PAH medication group, differences in costs between baseline and follow-up were statistically significant (p < 0.01) for all categories. For PAH diagnosis group, differences in costs between baseline and follow-up were statistically significant (p < 0.001) for all categories. Bars represent standard deviation.